Cel sci corp (CVM)
CashFlow / Yearly
Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10Sep'09
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-22,134

-31,837

-14,363

-11,512

-34,692

-27,352

-9,170

-15,477

-25,712

10,483

-40,910

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

633

650

632

663

720

745

364

533

531

516

417

Share-based payments for services

856

530

232

751

565

694

454

527

214

1,241

449

Share-based payments for interest

0

80

0

-

-

-

-

-

-

-

-

Modification of warrants issued to consultants

-

-

-

-

0

76

0

-

-

-

-

Equity based compensation

4,428

2,743

1,380

2,113

5,105

3,958

2,636

-

-

-

685

401(k) contributions paid in common stock

143

145

151

161

165

155

158

-

-

-

-

Shares issued for settlement of clinical research costs

3,400

5,507

1,310

0

-

-

-

-

-

-

-

Loss prepaid research and development

0

-471

0

-

-

-

-

-

-

-

-

Issuance of convertible notes and preferred stock in legal settlement

-

-

-

-

-

-

-

0

9,000

-

-

Extension of stock options issued to consultants

-

-

-

-

-

-

-

54

30

-

-

Issuance of convertible notes and preferred stock in legal settlment

-

-

-

-

-

-

-

-

-

0

-

Amortization of loan premium

-

-

-

-

-

-

-

-

-

-3

-

Extension of options issued to consultants

-

-

-

-

-

-

-

-

-

15

-

Extension of options issued to employees

-

-

-

-

-

-

-

36

105

212

-

Modification of stock options and warrants

-

-

-

-

-

-

-

-

-

-

6

Loss on conversion of convertible notes

-

-

-

-

-

-

-

-

-

-

2,145

Employee option cost

-

-

-

-

-

-

-

2,229

1,535

1,316

1,699

Common stock contributed to 401 (k) plan

-

-

-

-

-

-

-

154

150

112

57

Warrants issued in consideration for loan

-

-

-

-

-

-

-

-

-

-

65

Impairment loss on abandonment of patents

-

-

-

-

0

1

22

44

9

13

138

Loss on retired equipment

-

-

1

0

0

0

4

9

2

2

0

Loss on derivative instruments

-760

-8,643

11,007

14,013

282

248

10,750

-

-

-

-

Issuance of common stock for services

-

-

-

-

-

-

-

-

-

-

1,561

Premium on loan

-

-

-

-

-

-

-

-

-

-

341

Loan premium adjustment

-

-

-

-

-

-

-

-

-

-

489

Amortization of debt discount

0

1,956

917

0

-

-

0

-

-

-

-338

Inducement expense

0

291

0

-

-

-

-

-

-

-

-

Capitalized lease interest

-128

-168

-200

-227

249

241

-

-

-

-

-

Loss on debt extinguishment

-

-

-

-

-620

0

0

-

-

-

-

Loss (gain) on derivative instruments

-

-

-

-

-

-

-

1,911

4,432

-

-

(Increase)/decrease in assets:
Gain/loss on derivative instruments

-

-

-

-

-

-

-

-

-

-

25,514

(Increase)/decrease in deposits

-

-

-

-

-

-

-

-

-

-

4

Receivables

55

99

-129

-1

-5

-7

84

298

-457

0

-

Deferred rent

-

-

-

-

-

-

544

598

629

955

-

Decrease in deferred rent

-

-

-

-

-

-

-

-

-

-

622

Prepaid expenses

-137

153

151

15

-68

-158

529

775

-1,729

-258

-12

Supplies used for R&D and manufacturing

-137

27

336

393

50

-435

367

186

-94

-1,076

-4

Deposits

0

150

154

145

150

-200

-400

0

-1,670

-

-

Increase/(decrease) in liabilities:
Accounts payable

-4,084

-2,514

5,420

-2,389

3,981

-751

1,316

-168

-788

693

343

Accrued expenses

-170

-731

558

290

-458

433

101

-99

147

125

-14

Decrease in accrued interest on convertible debt

-

-

-

-

-

-

-

-

-

-

-2

Deferred revenue

-

-

-

-1

0

0

0

1

0

125

-

Due to employees

-55

71

256

72

57

-78

186

-2

-23

-3

13

Other liabilities

-6

4

1

-

-

-

-

-

-

-

-

Deferred rent liability

-

-

-

1

6

-3

-0

11

-3

0

7

Deposits held

-

-

-

-

-

-

-

5

0

-10

10

Net cash used in operating activities

-16,320

-13,389

-13,791

-23,082

-23,833

-22,928

-13,548

-12,190

-22,555

-12,804

-6,513

CASH FLOWS FROM INVESTING ACTIVITIES:
Additional investment in manufacturing facility

-

-

-

-

-

-

-

-

-

32

-

Additional investment in manufacturing facility

-

-

-

-

-

-

-

-

-

-

-505

Decrease in restricted cash

-

-

-

-

-

-

-

0

-21

-47

919

Sale of investments in available-for-sale securities

-

-

-

-

-

-

-

-

-

-

200

Purchases of property and equipment

177

1

10

31

73

103

102

54

216

493

-191

Expenditures for patent costs

158

57

6

2

20

34

30

78

122

25

-53

Net cash used in investing activities

-335

-58

-17

-34

-93

-138

-132

-133

-318

-503

368

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock

0

11,792

10,519

21,420

21,148

28,428

9,788

14,289

3,936

0

32,242

Payments of stock issuance costs

-

-

-

-

-

-

-

-

-

-

-2,072

Proceeds from short-term loan

-

-

-

-

-

-

-

-

-

-

3,104

Repayment of short-term loan

-

-

-

-

-

-

-

-

-

-

-2,200

Payment for repurchase of preferred stock

-

-

-

-

-

-

-

-

-

0

-754

Proceeds from the purchase of stock by officers and directors

291

385

0

-

-

-

-

-

-

-

-

Payments of stock issuance costs

-163

-195

-

-

-

-

-

-

-

-

-

Payment on related party loan

-

-

-

-1,104

-

-

-

-

-

-

-

Proceeds from issuance of notes payable

-

-

2,745

0

-

-

-

-

-

-

-

Proceeds from exercise of warrants

14,517

9,412

0

-

0

3,118

0

-

-

-

-

Proceeds from exercise of warrants and stock options

-

-

-

-

-

-

-

2,664

679

-

-

Payments for repurchase of preferred stock

-

-

-

-

-

-

-

0

4,050

-

-

Proceeds from exercises of options

-

-

-

-

-

-

-

-

-

6,308

8,681

Payments on convertible debt

-

-

-

-

-

-

-

4,950

0

0

-

Payments on obligations under capital lease

5

6

3

8

8

8

6

0

0

-

-

Net cash provided by financing activities

14,791

21,388

13,260

20,308

21,139

31,538

9,781

12,004

565

6,308

39,000

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

-1,865

7,940

-548

-2,808

-2,786

8,472

-3,899

-319

-22,307

-6,999

32,856

Decrease in common stock

-

-

-

-

-

-

0

-

-

-

-

Increase in discount on notes payable

-

-

-

-

-

-

-

-

-

-

245

Decrease in additional paid-in capital

-

-

-

-

-

-

-

6,706

0

0

8,632

Total

-

-

-

-

-

-

-

0

0

0

0

Increase in common stock

-

-

-

-

-

-

-

-8

0

0

-

Increase in additional paid-in capital

-

-

-

-

-

-

-

-241

0

0

-

Decrease in additional paid-in capital

-

-

-

-

-

-

-

-250

0

0

-

Total

-

-

-

-

-

-

-

0

0

0

-

Increase in additional paid-in capital

-

-

-

-

-

-

-

-1,593

0

-

-24

Total

-

-

-

-

-

-

-

-

-

0

0

Increase in additional paid-in capital

-

-

-

-

-

-

-

-

-

-1,532

-

Decrease in additional paid-in capital

-

-

-

-

-

-

-

-

-

-1,532

-

Decrease in additional paid-in capital

-

-

-

-

-

-

-

-

-

-

24

Total

-

-

-

-

-

-

-

-

-

0

0

Increase in additional paid-in capital

-

-

-

-

-

-

-

-

-

0

-

Decrease in additional paid-in capital

-

-

-

-

-

-

-

1,593

0

0

-

Total

-

-

-

-

-

-

-

0

0

0

-

Total

-

-

-

-

-

-

-

-

-

0

-

Increase in additional paid-in capital

-

-

-

-

-

-

-

-53

0

0

-

Increase in prepaid services

-

-

-

-

-

-

-

-53

0

0

-

Increase in patent costs

-

-

-

-

-

-

-

22

28

0

7

Total

-

-

-

-

-

-

-

0

0

-

-

Decrease in derivative liabilities

-

-

-

-

-

-

-

-122

-202

-5,510

-

Increase in additional paid-in capital

-

-

-

-

-

-

-

-122

-202

-5,510

-

Total

-

-

-

-

-

-

-

0

0

-

-

Increase additional paid-in capital

-

-

-

-

-

-

-

-325

-1,068

-

-

Decrease in additional paid in capital

-

-

-

-

-

-

-

325

1,068

-

-

Decrease in additional paid in capital

-

-

-

-

-

-

4,142

-

-

-

24

Total

-

-

-

-

-

-

0

-

-

-

-

Increase in accounts payable

-

-

-

-

-

-

-

-

-

-10

-15

Increase in accounts payable

-

-

-

-

-

-

-

-

-

0

-7

Increase in debt discount

-

-

-

-

-

-

-

-

-

-

65

Increase in additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-65

Total

-

-

-

-

-

-

-

-

-

-

0

Increase in common stock

-

-

-

-

-

-

-

-

-

-

-11

Increase additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-479

Increase accumulated deficit

-

-

-

-

-

-

-

-

-

-

490

Total

-

-

-

-

-

-

-

-

-

-

0

Increase in derivative liabilities

-

-

-

-

-

-

-

-

-

-6,186

-

Increase in accumulated deficit

-

-

-

-

-

-

-

-

-

6,186

-

Total

-

-

-

-

-

-

-

-

-

0

-

Total

-

-

-

-

-

-

-

0

0

-

-

Increase in additional paid-in-capital

-

-

-

-

-

-

-

-

-

0

-

Total

-

-

-

-

-

-

-

-

-

-

0

Decrease in accrued expenses

-

-

-

-

-

-

-

0

81

0

-

Increase in additional paid-in capital

-

-

-

-

-

-

-

0

-81

0

-

Total

-

-

-

-

-

-

-

0

0

-

-

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of warrants issued in connection with public offering

-

-

-4,665

-

-

-

-

-

-

-

-

Conversion of notes payable to common stock

-

-

-

0

-

-

-

-

-

-

-

Plant, property and equipment purchases included in accounts payable

17

0

-

-

-

-

-

-

-

-

-

Forfeiture of unvested restricted stock

-

-

-

-

1

0

-

-

-

-

-

Stock issued under an anti-dilution provision and cashless exercise of warrants

-

-

-

-

0

-16

-

-

-

-

-

Prepaid consulting services paid with issuance of common stock

22

162

-3

18

3

31

57

-

-

-

-

Conversion of accrued salaries and fees to notes payable

-

-

275

0

-

-

-

-

-

-

-

Conversion of notes payable to common stock

0

2,294

450

-

-

-

-

-

-

-

-

Exercise of derivative liabilities

3,589

1,379

0

-

-

-

-

-

-

-

-

Research and office equipment included in accounts payable at year end

-

-

-

-

-2

-1

36

-

-

-

-

Decrease (increase) in capital lease obligation

-

-

-

-

-

-

-35

-

-

-

-

Capitalizable patent costs included in accounts payable at year end

-

-

-

-

-11

4

14

-

-

-

-

Total

-

-

-

-

-

-

-

0

0

0

-

Increase in accounts payable

-

-

-

-

-

-

-

-22

-28

-

-

Total

-

-

-

-

-

-

-

0

0

-

-

Total

-

-

-

-

-

-

-

-

-

0

0

Increase in research and office equipment

-

-

-

-

-

-

-

0

1

-10

15

Decrease (increase) in capital lease obligation

-

-

-

-

-

-

-

0

-1

-

-

Patent costs purchased with common stock

-

-

-

-

0

9

0

-

-

-

-

Lease payments included in accounts payable at year end

0

0

1

0

0

3

-

-

-

-

-

Stock issuance costs included in current liabilities

15

46

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-6

-

(Gain)/loss on derivative instruments

-

-

-

-

-

-

-

-

-

-28,843

-

Deposits

-

-

-

-

-

-

-

-

-

1,585

-

Discount on notes payable

-

-

-

-

-

-

-

-

-

-

193

Decrease (increase) in accounts payable

-

-

-

-

-

-

-14

-

-

-

-

Total

-

-

-

-

-

-

0

-

-

-

-

Decrease in convertible debt

-

-

-

-

-

-

-

-

-

-

1,206

Increase in common stock

-

-

-

-

-

-

-

-

-

-

-30

Increase in additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-1,176

Total

-

-

-

-

-

-

-

-

-

-

0

Decrease in accrued liabilities

-

-

-

-

-

-

-

-

-

-

42

Increase in common stock

-

-

-

-

-

-

-

-

-

-

-1

Increase in additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-41

Total

-

-

-

-

-

-

-

-

-

-

0

Decrease in convertible debt

-

-

-

-

-

-

-

-

-

-

285

Increase in common stock

-

-

-

-

-

-

-

-

-

-

-9

Increase in additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-275

Total

-

-

-

-

-

-

-

-

-

-

0

Fair value of warrant liabilities on the date of issuance reclassed to liabilities

-

-

-

-8,722

-8,463

-5,320

-4,200

-6,706

0

0

-8,877

Total

-

-

-

-

-

-

-

-

-

0

0

Decrease in capital lease obligation

-

-

-

-

-

-

-

0

0

-

-

Financing costs included in accounts payable at year end

-

-

35

46

0

0

-

-

-

-

-

Receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services

-

-

-305

305

0

0

-

-

-

-

-

Increase in accounts payable

-

-

-

-

-

-

-

0

0

-

-

Total

-

-

-

-

-

-

-

0

0

-

-

Cash paid for interest

1,809

1,750

1,888

1,900

1,969

1,965

156

377

195

162

115